Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.
J Diabetes Investig. 2019 Sep;10(5):1171-1173. doi: 10.1111/jdi.13123. Epub 2019 Aug 20.
Accumulating clinical data on incretin-based dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in the past decade have clearly confirmed their safety and efficacy as antidiabetes drugs. However, the journey to understand the incretin system and its role in health and disease continues.
在过去十年中，不断积累的基于肠促胰岛素的二肽基肽酶-4 抑制剂和胰高血糖素样肽-1 受体激动剂的临床数据，明确证实了它们作为抗糖尿病药物的安全性和有效性。然而，人们对肠促胰岛素系统及其在健康和疾病中的作用的认识仍在不断深入。
